Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 2
1975 1
1976 2
1978 2
1979 2
1980 7
1981 5
1982 6
1983 11
1984 6
1985 2
1986 3
1987 10
1988 7
1989 8
1990 10
1991 8
1992 18
1993 4
1994 5
1995 4
1996 8
1997 3
1998 2
1999 2
2000 3
2001 4
2003 2
2004 1
2007 1
2008 2
2009 2
2010 3
2011 2
2013 2
2014 2
2015 2
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Results by year

Filters applied: . Clear all
Page 1
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; Study group indolent Lymphomas (StiL). Rummel MJ, et al. Among authors: niederle n. Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20. Lancet. 2013. PMID: 23433739 Clinical Trial.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. Heinemann V, et al. Among authors: niederle n. Lancet Oncol. 2014 Sep;15(10):1065-75. doi: 10.1016/S1470-2045(14)70330-4. Epub 2014 Jul 31. Lancet Oncol. 2014. PMID: 25088940 Clinical Trial.
[Prevention, diagnosis, therapy, and follow-up of lung cancer].
Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, Niederle N, Stuschke M, Blum T, Deppermann KM, Ficker JH, Freitag L, Lübbe AS, Reinhold T, Späth-Schwalbe E, Ukena D, Wickert M, Wolf M, Andreas S, Auberger T, Baum RP, Baysal B, Beuth J, Bickeböller H, Böcking A, Bohle RM, Brüske I, Burghuber O, Dickgreber N, Diederich S, Dienemann H, Eberhardt W, Eggeling S, Fink T, Fischer B, Franke M, Friedel G, Gauler T, Gütz S, Hautmann H, Hellmann A, Hellwig D, Herth F, Heussel CP, Hilbe W, Hoffmeyer F, Horneber M, Huber RM, Hübner J, Kauczor HU, Kirchbacher K, Kirsten D, Kraus T, Lang SM, Martens U, Mohn-Staudner A, Müller KM, Müller-Nordhorn J, Nowak D, Ochmann U, Passlick B, Petersen I, Pirker R, Pokrajac B, Reck M, Riha S, Rübe C, Schmittel A, Schönfeld N, Schütte W, Serke M, Stamatis G, Steingräber M, Steins M, Stoelben E, Swoboda L, Teschler H, Tessen HW, Weber M, Werner A, Wichmann HE, Irlinger Wimmer E, Witt C, Worth H; Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin und die Deutsche Krebsgesellschaft. Goeckenjan G, et al. Among authors: niederle n. Pneumologie. 2010 Mar;64 Suppl 2:e1-164. doi: 10.1055/s-0029-1243837. Epub 2010 Mar 9. Pneumologie. 2010. PMID: 20217630 German. No abstract available.
Development and mechanisms of interferon resistance.
Kloke O, Niederle N. Kloke O, et al. Among authors: niederle n. Cancer Treat Rev. 1990 Dec;17 Suppl A:81-8. doi: 10.1016/0305-7372(90)90019-c. Cancer Treat Rev. 1990. PMID: 1709389 Review. No abstract available.
[Molecular genetic tests in advanced non-small cell lung cancer: practical relevance].
Sebastian M, Niederle N, Thomas M, Reck M, Schmittel A, Fischer B, Overbeck T, Gröschel A, Deppermann M, Pirker R, Huber RM, Eberhardt W, Griesinger F. Sebastian M, et al. Among authors: niederle n. Dtsch Med Wochenschr. 2014 Oct;139(41):2096-100. doi: 10.1055/s-0034-1387294. Epub 2014 Sep 30. Dtsch Med Wochenschr. 2014. PMID: 25268213 Review. German. No abstract available.
[Chemotherapy in advanced sarcomas (author's transl)].
Bierbaum W, Bremer K, Firusian N, Higi M, Niederle N, Scheulen ME, Schmidt CG, Seeber S. Bierbaum W, et al. Among authors: niederle n. Dtsch Med Wochenschr. 1981 Sep 11;106(37):1181-5. doi: 10.1055/s-2008-1070478. Dtsch Med Wochenschr. 1981. PMID: 7200859 Clinical Trial. German.
[Felty's syndrome].
Niederle N, Mohr R, Mohr HJ. Niederle N, et al. Med Welt. 1976 Nov 5;27(45):2145-8. Med Welt. 1976. PMID: 994832 German. No abstract available.
162 results